Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-24 @ 4:02 PM
NCT ID:
NCT00020566
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed tumor of the Ewing's family of bone or soft tissue
* Ewing's sarcoma
* Peripheral primitive neuroectodermal tumor
* Disease meeting one of the following criteria:
* Resectable localized disease (tumor volume less than 200 mL)
* Localized disease previously resected at diagnosis
* Unresectable disease (at least 200 mL tumor volume) but radiotherapy as local control can be delayed
* Localized disease with early radiotherapy required
* Pulmonary and/or pleural metastases only
* Extrapulmonary/pleural metastases (skeleton, bone marrow, lymph nodes)
* No more than 45 days since definitive biopsy
PATIENT CHARACTERISTICS:
Age:
* Under 50
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Renal function normal
* Glomerular filtration rate at least 60 mL/min
Cardiovascular:
* Normal cardiac function
* Fractional shortening at least 29%
* Ejection fraction at least 40%
Other:
* No medical, psychiatric, or social condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
49 Years
Study:
NCT00020566
Study Brief:
Protocol Section:
NCT00020566